DiaMedica Therapeutics to Present at CKD3 Kidney Summit Meeting

DiaMedica Therapeutics (Nasdaq: DMAC) has announced that Dr. Harry Alcorn, Chief Medical Officer, will present a research update on CKD DM199 at the 3rd Chronic Kidney Disease Drug Development summit on March 2, 2021, at 1:00 PM ET.

Rhea-AI Impact

(Neutral)

Rhea-AI Sentiment

(Neutral)How Sentiment works

Sentiment and the balance of points

Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.

How Sentiment works How the balance works

Tags

conferences

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google

02/25/2021 - 08:48 AM

DiaMedica Therapeutics Inc. (Nasdaq: DMAC), a clinical stage biopharmaceutical company developing novel treatments for neurological and kidney diseases, today announced that Dr. Harry Alcorn, its Chief Medical Officer will be presenting “CKD DM199 Research Update” at the 3^rd Chronic Kidney Disease Drug Development (“CKD3”) summit virtually on Tuesday March 2^nd, 2021, at 1:00pm Eastern Time. The presentation will include data from the CKD Phase 1b study and an overview of the CKD Phase II Redux study design.

The 3rd CKD3 Summit is the industry’s definitive forum dedicated to developing more innovative, targeted and clinically successful drugs to more meaningfully address chronic kidney disease. CKD3 is a uniquely focused conference that unites key opinion leaders to identify and discuss critical factors in determining the success of current chronic kidney disease (“CKD”) pipelines and evaluate new treatments that have the potential to significantly impact the standard of care for this serious unmet medical need. Leading experts from innovative biotechnology and pharmaceutical companies, academia and key service providers come together at the CKD3 summit to present comprehensive insight into the cutting-edge progress of CKD drug development research. This year’s summit is being held virtually.

About DiaMedica Therapeutics Inc.

DiaMedica Therapeutics Inc. (Nasdaq: DMAC) is a clinical stage biopharmaceutical company focused on developing novel treatments to improve the lives of patients with neurological and chronic kidney diseases. To learn more about DiaMedica, visit www.diamedica.com.